ABAB Pedia

DCVC

DCVC (Data Collective) is an American deep tech venture capital firm founded in 2010 by Matt Ocko and Zachary Bogue, with offices in Palo Alto and San Francisco, California. It invests in companies that use computing and AI to solve real-world problems in fields such as energy, climate, biomedicine, defense, space, and industry; as of October 2026 it had more than $4 billion in assets under management across 13 funds.

Contents11 sections
Key facts

Founding

DCVC was founded in 2010 by Matt Ocko and Zachary Bogue, who as of October 2026 remain its co-founders and managing partners. DCVC says its founding mission was to support deep tech founders pushing the limits of emerging technology to solve “trillion-dollar problems”; while most of its peers focused on the consumer web and enterprise SaaS, it invested in companies using a computational advantage to transform vital industries that had seen little change in decades. DCVC also says that one of its founders coined the term “deep tech” with a friend about 25 years ago.⁠[1][2][3][1][1]

DCVC says that scale-out computing companies it backed early became building blocks of AWS, Microsoft Azure, Google Cloud, Illumina, and VMware.⁠[5]

Fifth and Sixth Funds

At the beginning of 2016, DCVC raised and closed its fifth and sixth funds in less than 90 days: the fifth was an early-stage seed and Series A fund, and the sixth an “opportunity fund” for larger follow-on bets in its most successful early-stage companies.⁠[6][6][6]

Expansion to $387 Million

On March 11, 2017, DCVC announced that, at the request of several large new institutional investors, it had expanded its previously closed fifth and sixth funds to a combined $387 million. Portfolio companies it named at the time included Zymergen, Planet, LendUp, Nervana (later acquired by Intel), Freenome, SentinelOne, Tala, Rigetti, Primer, Kindred, Atomwise, and Karius; DCVC also described its “Collective” model, in which a team of venture capitalists works with more than 50 technology executives and experts to support founders, all of whom have an economic interest in the funds.⁠[6][6][6][6][6][6][6]

Launch of DCVC Bio

In 2018, DCVC launched its life sciences investment arm, DCVC Bio, co-founded by its four managing partners Ocko, Bogue, John Hamer, and Kiersten Stead, to invest in platform companies that use AI and large data models to discover new medicines and drive other biological breakthroughs. DCVC Bio says that, unlike most biotechnology funds, it does not bet on specific drugs or molecules but invests in scientific breakthroughs and computation-enhanced platforms that can repeatedly generate results.⁠[7][8][8]

More Than $1 Billion in New Capital and Four New General Partners

On July 21, 2023, DCVC announced it had raised more than $1 billion in new capital and released its first Deep Tech Opportunities Report. The same day, Alan Cohen, James Hardiman, Jason Pontin, and Ali Tamaseb were promoted to general partner; Hardiman, a physicist who has been with DCVC since 2014, has led investments in AI platforms applied to biology, manufacturing, and materials design, as well as in areas such as quantum computing.⁠[5][5][9][9][9][9]

First Climate Fund and DCVC Bio III

On September 30, 2024, DCVC announced that two new funds had raised more than $700 million combined, bringing the total it had closed over the previous two and a half years to more than $1.6 billion. The two funds were DCVC’s first dedicated climate fund and DCVC Bio III, its third main life sciences fund, which was oversubscribed at $400 million against an original target of $350 million. Early investments of the climate fund included the geothermal company Fervo Energy and Twelve, which makes sustainable aviation fuel from carbon dioxide.⁠[1][1][1][8][8][1][1]

Portfolio Company Fervo Energy Goes Public

On May 13, 2026, Fervo Energy, an enhanced geothermal systems company in which DCVC has invested since 2022, went public on Nasdaq (ticker FRVO); Bogue and general partner Rachel Slaybaugh joined the opening bell ceremony.⁠[10][10][10][10]

Leading TypeSafe AI’s Seed Round

Scale, Team, and Investment Focus

As of October 2026, by DCVC’s own figures, it had more than $4 billion in assets under management, a team of about 50, more than 200 portfolio companies, and 13 funds, six of them flagship funds and three of them DCVC Bio funds; its offices are in Palo Alto and San Francisco. DCVC describes its team as having “more published scientists than MBAs.”⁠[7][7][7][7][14][14][14]

The investment areas DCVC lists include AI, compute and quantum; computational biology and chemistry; cybersecurity, security, and defense; energy and climate; finance and insurance; industrial transformation and advanced manufacturing; next-generation agriculture; space; and TechBio and TechMed.⁠[14]

Related Organizations, Websites, and Public Accounts

Sources

  1. DCVC closes $700 million+ in new funds for a healthier planet and healthier lives (opens in a new window)
  2. Zachary Bogue, Co-Founder and Managing Partner (opens in a new window)
  3. DCVC | Team (opens in a new window)
  4. Matthew Ocko, Co-Founder and Managing Partner (opens in a new window)
  5. DCVC announces $1 billion in fresh funding; releases inaugural DCVC Deep Tech Opportunities Report (opens in a new window)
  6. Data Collective Tops Up Previously Closed Fifth and Sixth Funds for a New Total of $387 Million (opens in a new window)
  7. DCVC | About (opens in a new window)
  8. DCVC Bio III closes at $400 million (opens in a new window)
  9. DCVC promotes four Partners to General Partner (opens in a new window)
  10. Fervo IPO (opens in a new window)
  11. TypeSafe emerges from stealth with a new way of doing AI (opens in a new window)
  12. TypeSafe AI exits stealth with $40M to build AI for use by software (opens in a new window)
  13. TypeSafe A raises Series AI (opens in a new window)
  14. DCVC | Home (opens in a new window)